PTPRD mutant subgroup had better response to ICB treatment, with ORR, DCR and DCB as 40.00%, 60.00%, and 52.94% respectively (Fig. 1B). PTPRD mutation was associated with higher TMB...PTPRD mutation is a positive predictive biomarker of NSCLC ICB therapy, which may be associated with TMB. Moreover, PTPRD mutation can help identifying patients with larger probability of benefiting from ICB treatment, among patients with high TMB.